Cargando…
Adherence to ASCO for Prophylaxis of Acute Chemotherapy-Induced Nausea and Vomiting in Iran
INTRODUCTION: Chemotherapy-induced nausea and vomiting (CINV) is one of the scariest chemotherapy-induced adverse effects. We evaluated the adherence to the 2017 American Society of Clinical Oncology (ASCO), the latest guideline recommendations, for the management of acute CINV at our institute. MET...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
West Asia Organization for Cancer Prevention
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7568894/ https://www.ncbi.nlm.nih.gov/pubmed/32592350 http://dx.doi.org/10.31557/APJCP.2020.21.6.1567 |
_version_ | 1783596616099299328 |
---|---|
author | Ebrahimi, Mahbobeh Mehrzad, Valiollah Moghaddas, Azadeh |
author_facet | Ebrahimi, Mahbobeh Mehrzad, Valiollah Moghaddas, Azadeh |
author_sort | Ebrahimi, Mahbobeh |
collection | PubMed |
description | INTRODUCTION: Chemotherapy-induced nausea and vomiting (CINV) is one of the scariest chemotherapy-induced adverse effects. We evaluated the adherence to the 2017 American Society of Clinical Oncology (ASCO), the latest guideline recommendations, for the management of acute CINV at our institute. METHODS: During a 6-months cross-sectional study on outpatient’s cancer patients, we collected data from the prescription documents during temporary hospitalization and compared the results with ASCO guideline recommendations. RESULTS: The most prescribed prophylactic regimens for the management of CINV were combination of aprepitant, granisetron, and dexamethasone and metoclopramide (51.8%). Regarding prescription compatibility in our center with ASCO guideline recommnedations, selection of different regimens for prophylaxis of acute CINV in our institute was compliant in 0 %, 22%, 4%, and 40% of high, moderate, low, and minimal emetogenic potential of chemotherapy regimen groupss, respectively. CONCLUSION: Although our hospital is a referral and university-affiliated center, adherence to the ASCO guideline recommendations for prophylaxis of CINV was poor. |
format | Online Article Text |
id | pubmed-7568894 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | West Asia Organization for Cancer Prevention |
record_format | MEDLINE/PubMed |
spelling | pubmed-75688942020-10-30 Adherence to ASCO for Prophylaxis of Acute Chemotherapy-Induced Nausea and Vomiting in Iran Ebrahimi, Mahbobeh Mehrzad, Valiollah Moghaddas, Azadeh Asian Pac J Cancer Prev Research Article INTRODUCTION: Chemotherapy-induced nausea and vomiting (CINV) is one of the scariest chemotherapy-induced adverse effects. We evaluated the adherence to the 2017 American Society of Clinical Oncology (ASCO), the latest guideline recommendations, for the management of acute CINV at our institute. METHODS: During a 6-months cross-sectional study on outpatient’s cancer patients, we collected data from the prescription documents during temporary hospitalization and compared the results with ASCO guideline recommendations. RESULTS: The most prescribed prophylactic regimens for the management of CINV were combination of aprepitant, granisetron, and dexamethasone and metoclopramide (51.8%). Regarding prescription compatibility in our center with ASCO guideline recommnedations, selection of different regimens for prophylaxis of acute CINV in our institute was compliant in 0 %, 22%, 4%, and 40% of high, moderate, low, and minimal emetogenic potential of chemotherapy regimen groupss, respectively. CONCLUSION: Although our hospital is a referral and university-affiliated center, adherence to the ASCO guideline recommendations for prophylaxis of CINV was poor. West Asia Organization for Cancer Prevention 2020-06 /pmc/articles/PMC7568894/ /pubmed/32592350 http://dx.doi.org/10.31557/APJCP.2020.21.6.1567 Text en This is an Open Access article distributed under the terms of the Creative Commons Attribution License, (http://creativecommons.org/licenses/by/3.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Ebrahimi, Mahbobeh Mehrzad, Valiollah Moghaddas, Azadeh Adherence to ASCO for Prophylaxis of Acute Chemotherapy-Induced Nausea and Vomiting in Iran |
title | Adherence to ASCO for Prophylaxis of Acute Chemotherapy-Induced Nausea and Vomiting in Iran |
title_full | Adherence to ASCO for Prophylaxis of Acute Chemotherapy-Induced Nausea and Vomiting in Iran |
title_fullStr | Adherence to ASCO for Prophylaxis of Acute Chemotherapy-Induced Nausea and Vomiting in Iran |
title_full_unstemmed | Adherence to ASCO for Prophylaxis of Acute Chemotherapy-Induced Nausea and Vomiting in Iran |
title_short | Adherence to ASCO for Prophylaxis of Acute Chemotherapy-Induced Nausea and Vomiting in Iran |
title_sort | adherence to asco for prophylaxis of acute chemotherapy-induced nausea and vomiting in iran |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7568894/ https://www.ncbi.nlm.nih.gov/pubmed/32592350 http://dx.doi.org/10.31557/APJCP.2020.21.6.1567 |
work_keys_str_mv | AT ebrahimimahbobeh adherencetoascoforprophylaxisofacutechemotherapyinducednauseaandvomitinginiran AT mehrzadvaliollah adherencetoascoforprophylaxisofacutechemotherapyinducednauseaandvomitinginiran AT moghaddasazadeh adherencetoascoforprophylaxisofacutechemotherapyinducednauseaandvomitinginiran |